Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2018 Annual Meeting

NEW YORK, NY, May 17, 2018

Flatiron Health today announced 11 abstracts accepted for presentation at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-5 in Chicago. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s highly-curated, nationally-representative, real-world oncology datasets, the largest in the United States.

The research to be presented includes collaborations with the Abramson Cancer Center of the University of Pennsylvania, Fred Hutchinson Cancer Research Center, Genentech (a member of the Roche Group), Huntsman Cancer Institute at the University of Utah, the National Cancer Institute, Roche, the U.S. Food & Drug Administration, and Yale Cancer Center.

The presentation schedule and links to abstracts can be found below. To learn more about Flatiron Health, visit our booth #2049 during the conference or click here.

Oral Presentation

Application of a real-world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC)

Presenting Author: Greg Riely (Memorial Sloan Kettering Cancer Center)

Date/Time: 6/5/2018, 10:00 – 10:12 AM

Abstract: #12006

Location: S406

Session: Tumor Biology

Poster Discussion Presentation

Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients

Presenting Author: Lotte Steuten (Fred Hutchinson Cancer Research Center)

Date/Time: 6/2/2018, 4:45 – 6:00 PM

Abstract: #6513

Poster: #339

Location: S102

Session: Health Services Research, Clinical Informatics, and Quality of Care

Poster Presentations (Location: Hall A)

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)

Presenting Author: Ashwini Shewade (Genentech, a member of the Roche Group)

Date/Time: 6/2/2018, 8:00 – 11:30 AM

Abstract: #1037

Poster: #118

Session: Breast Cancer—Metastatic

Diffusion of innovation in oncology: A case study of immuno-oncology (IO) adoption for advanced non-small lung cancer (aNSCLC) patients across practices in the US

Presenting Author: Carrie Bennette (Flatiron Health)

Date/Time: 6/2/2018, 1:15 – 4:45 PM

Abstract: #6537

Poster: #363

Session: Health Services Research, Clinical Informatics, and Quality of Care

Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P)

Presenting Author: Jizu Zhi (U.S. Food & Drug Administration)

Date/Time: 6/2/2018, 1:15 – 4:45 PM

Abstract: #6553

Poster: #379

Session: Health Services Research, Clinical Informatics, and Quality of Care

Development of a dashboard for end-of-life care at an academic hospital

Presenting Author: Kerin Adelson (Yale Cancer Center)

Date/Time: 6/2/2018, 1:15 PM – 4:45 PM

Abstract: #6590

Poster: #415

Session: Health Services Research, Clinical Informatics, and Quality of Care

Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies

Presenting Author: Michael W Lu (Genentech, a member of the Roche Group)

Date/Time: 6/2/2018, 1:15 – 4:45 PM

Abstract: #6578

Poster: #403

Session: Health Services Research, Clinical Informatics, and Quality of Care

Comparative effectiveness of carboplatin-pemetrexed (carbo-pem) with vs without bevacizumab (bev) in patients with advanced non-squamous (sq) non-small cell lung cancer (NSCLC)

Presenting Author: Stephen Bagley (Abramson Cancer Center of the University of Pennsylvania)

Date/Time: 6/3/18, 8:00 – 11:30 AM

Abstract: #9073

Poster: #396

Session: Lung Cancer—Non-Small Cell Metastatic

Age-related real-world outcomes for patients (pts) with metastatic colorectal cancer (mCRC)

Presenting Author: Rebecca Miksad (Flatiron Health)

Date/Time: 6/3/2018, 8:00 – 11:30 AM

Abstract: #3613

Poster: #106

Session: Gastrointestinal (Colorectal) Cancer

Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with hepatic or renal dysfunction (dysf): Real-world patient characteristics and outcomes

Presenting Author: Susan Spillane (National Cancer Institute)

Date/Time: 6/4/2018, 1:15 – 4:45 PM

Abstract: #9569

Poster: #396

Session: Melanoma/Skin Cancers

Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer

Presenting Author: Shiven Patel (Huntsman Cancer Institute at the University of Utah)

Date/Time: 6/4/2018, 1:15 – 4:45 PM

Abstract: #10101

Poster: #89

Session: Patient and Survivor Care

About Flatiron

Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 265 community cancer clinics, seven major academic research centers and the top 15 therapeutic oncology companies. For more information, please visit www.flatiron.com or follow us @FlatironHealth.